Contact: Bill Schaller
Dana-Farber Cancer Institute
Caption: Geoffrey Shapiro, M.D., and colleagues at Dana-Farber Cancer Institute have demonstrated a molecular strategy they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs.
Credit: Sam Ogden
Usage Restrictions: None
Related news release: Blocking molecular target could make more cancers treatable with PARP inhibitors